NDA 022006 · Lundbeck Pharms LLC
Sabril
Vigabatrin · Oral · Anti-epileptic Agent
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 21, 2009
Approved uses
4
Original approval plus efficacy supplements
Registered trials
28
6 Phase 3, 2 recruiting
FAERS reports
13,897
9,744 serious, 1,337 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PERMANENT VISION LOSS SABRIL can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability . In some cases, SABRIL also can damage the central retina and may decrease visual acuity [see Warnings and Precautions ( 5.1 )]. The onset of vision loss from SABRIL is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years. Symptoms of vision loss from SABRIL are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Vision assessment is...
What it is approved for
From the label in effect Oct 20, 2021.
SABRIL is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; SABRIL is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) SABRIL is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions ( 5.1 )] . SABRIL is not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) SABRIL is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions ( 5.1 ) ].
Mechanism: The precise mechanism of vigabatrin’s anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. No direct correlation between plasma concentration and efficacy has been established. The duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the...
Therapeutic areas: Neurology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2020 Supplement 23 · Efficacy OrphanLetterLabel
- Oct 26, 2013 Supplement 13 · Efficacy · priority review LetterLabel
- Oct 26, 2013 Supplement 12 · Efficacy · priority review OrphanLabelLetter
- Aug 21, 2009 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewOtherSummary Review
1 products under this application
- SABRIL · VIGABATRIN 500MG/PACKET · FOR SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Vigabatrin" as an intervention, any sponsor and status, largest first.
- A Novel Approach to Infantile SpasmsPivotal-lookingSuspended
University of Colorado, DenverAcademic, hospital or other
NCT03347526 · 394 participants (planned) · Start Apr 19, 2018 · Primary completion Jun 2021
Drug: Cosyntropin Injectable Suspension, 1 mg/mL; Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin and 1 more · For: Infantile Spasm
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 14 sites in all
- Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile SpasmPivotal-lookingRecruiting
Kullasate SakpichaisakulGovernment (non-federal)
NCT04302116 · 250 participants (planned) · Start May 18, 2020 · Primary completion Jun 2026
Drug: Combination therapy with vigabatrin and prednisolone; Vigabatrin Tablets · For: Infantile Spasm; West Syndrome
Sites: Ratchathewi, Thailand
- Vigabatrin for the Treatment of Cocaine DependencyPivotal-lookingCompleted
Catalyst Pharmaceuticals, Inc.Industry
NCT01281202 · 207 participants · Start Jan 2011 · Primary completion Oct 2012
Drug: Vigabatrin; Matching Placebo · For: Cocaine Addiction; Cocaine Dependence
Sites: Los Angeles, California; Torrance, California; Denver, Colorado · 13 sites in all
- Vigabatrin for Treatment of Cocaine DependencePivotal-lookingCompleted
Catalyst Pharmaceuticals, Inc.Industry
NCT00611130 · 186 participants · Start Jan 2008 · Primary completion May 2009
Drug: vigabatrin; placebo · For: Cocaine Dependence
Sites: Little Rock, Arkansas; San Francisco, California; Torrance, California · 11 sites in all
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
- Double Blind Study of Vigabatrin for the Treatment of Cocaine DependencePivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT00527683 · 100 participants · Start Apr 2007 · Primary completion Nov 2007
Drug: Vigabatrin; Placebo · For: Cocaine Dependence
Sites: Mexico City, Mexico
Martina BebinAcademic, hospital or other
NCT02849457 · 84 participants · Start Dec 2016 · Primary completion Apr 26, 2023
Drug: Early Vigabatrin; Delayed Vigabatrin (Placebo) · For: Tuberous Sclerosis Complex
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 13 sites in all
Lundbeck LLCIndustry
NCT01278173 · 65 participants · Start Dec 2010 · Primary completion May 2015
Drug: Sabril · For: Adult Refractory Complex Partial Seizures
Sites: San Francisco, California; New Haven, Connecticut; Dover, Delaware · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure2,541
- drug ineffective1,368
- drug dose omission990
- death842
- pneumonia521
- somnolence508
- drug withdrawal convulsions482
- off label use443
- vomiting414
- hospitalisation369
- product dose omission issue366
- epilepsy302
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 23 |
| 2006 | 28 |
| 2007 | 18 |
| 2008 | 65 |
| 2009 | 39 |
| 2010 | 275 |
| 2011 | 219 |
| 2012 | 280 |
| 2013 | 211 |
| 2014 | 1,266 |
| 2015 | 1,569 |
| 2016 | 1,483 |
| 2017 | 1,220 |
| 2018 | 959 |
| 2019 | 785 |
| 2020 | 736 |
| 2021 | 786 |
| 2022 | 887 |
| 2023 | 1,001 |
| 2024 | 910 |
| 2025 | 672 |
| 2026 | 446 |
Recalls
1 FDA enforcement reports for this application.
Aug 17, 2023 · Class III · Completed
Cross contamination with other products
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sabril (Vigabatrin)
2024 spending
$15.2M
Beneficiaries
41
342 claims
Per beneficiary
$370,617
$197.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,348,728 |
| 2021 | $18,658,682 |
| 2022 | $20,044,400 |
| 2023 | $18,489,554 |
| 2024 | $15,195,305 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
- Vigabatrin.
Reynolds EH · BMJ 1990 · Clinical Trial, Review
- Vigabatrin.
Michelucci R, Tassinari CA · Epilepsy Res Suppl 1991 · Clinical Trial, Randomized Controlled Trial
- Anticonvulsants for cocaine dependence.
Minozzi S, Cinquini M, Amato L, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Lundbeck Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.